Innovative Trial Designs Are 'Life And Death Matter' For Pharma, Amgen Tells US FDA
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.
You may also be interested in...
BIO and PhRMA ask agency to provide more guidance on trial implementation, data integrity and novel data sources.
The Center for Biologics Evaluation and Research may need more fee revenue to add employees to handle the increasing cell and gene therapy workload.
Levy, SVP of global development, notes that two years after launching an in-house Center for Design and Analysis, Amgen considers adaptive designs for most new studies and more than half include adaptive elements.